Published in J Exp Med on October 01, 1987
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A (1991) 3.19
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med (1990) 2.02
'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev (2007) 1.98
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev (2004) 1.92
Constitutive synthesis of tumor necrosis factor in the thymus. Proc Natl Acad Sci U S A (1992) 1.89
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 1.77
Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest (1999) 1.72
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res (2009) 1.64
Bacterial cell wall-induced immunosuppression. Role of transforming growth factor beta. J Exp Med (1988) 1.64
Induction of transforming growth factor beta 1 by purified protein derivative of Mycobacterium tuberculosis. Infect Immun (1995) 1.52
Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer (1988) 1.51
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol (2015) 1.42
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol (2005) 1.35
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A (1996) 1.30
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 1.29
Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med (1990) 1.28
Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol (1990) 1.21
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 1.18
A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest (1998) 1.13
Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol (1990) 1.09
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. J Exp Med (1993) 1.07
Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol (1995) 1.05
Negative regulators in homeostasis of naïve peripheral T cells. Immunol Res (2008) 1.05
A transforming growth factor beta 2 (TGF-beta 2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus. J Exp Med (1990) 1.03
Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol (2001) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains. Infect Immun (1998) 1.01
Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-beta (TGF-beta) with histological rejection. Clin Exp Immunol (1993) 0.98
Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. Br J Cancer (1995) 0.94
CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest (1998) 0.93
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta. J Immunother (2007) 0.91
TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology (1989) 0.91
Murine and bovine γδ T cells enhance innate immunity against Brucella abortus infections. PLoS One (2011) 0.91
Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One (2012) 0.91
Transforming growth factor beta is protective in host resistance against Listeria monocytogenes infection in mice. Infect Immun (1996) 0.90
CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci U S A (2001) 0.90
Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. Am J Pathol (1993) 0.90
Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol (1992) 0.88
Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol (2002) 0.87
Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol (1996) 0.86
Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts. Am J Pathol (1997) 0.85
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J Immunol (1994) 0.84
Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN. Immunology (1994) 0.83
Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol (2008) 0.82
Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors. Immunology (1990) 0.82
Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity. PLoS One (2013) 0.82
Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma. Proc Natl Acad Sci U S A (1990) 0.82
Update on the immunological pathway of negative regulation in acute insults and sepsis. J Interferon Cytokine Res (2012) 0.81
Transforming growth factor beta 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages. Infect Immun (1994) 0.81
Inhibition of TGF-β1 signaling promotes central memory T cell differentiation. J Immunol (2013) 0.81
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J Immunol (1992) 0.81
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer (1992) 0.81
Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes. Immunology (1993) 0.79
Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1. Ann Surg (1994) 0.79
Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol (1991) 0.79
Epitope-specific CD8+ T cells play a differential pathogenic role in the development of a viral disease model for multiple sclerosis. J Virol (2012) 0.79
Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I. Immunology (1998) 0.79
The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta. Immunology (1996) 0.78
Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis (2000) 0.78
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A (2016) 0.78
The production of chemotactic cytokines in an allogeneic response. The role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3. Am J Pathol (1993) 0.77
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology (2016) 0.77
Augmentation of natural killer cell activity in mice by oral administration of transforming growth factor-beta. Immunology (1998) 0.76
T-cell Exhaustion and Cancer Immunotherapy. J Int Oral Health (2015) 0.75
Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc (1991) 0.75
Production of TGF-beta1 as a Mechanism for Defective Antigen-presenting Cell Function of Macrophages Generated in vitro with M-CSF. Immune Netw (2009) 0.75
Production of lipopolysaccharide-induced tumour necrosis factor during influenza virus infection in mice coincides with viral replication and respiratory oxidative burst. Mediators Inflamm (1995) 0.75
Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model. Oncotarget (2017) 0.75
Application of the multiplex cytokine analysis to monitor xenogeneic immune responses to the porcine islet graft in non-human primate. J Korean Med Sci (2013) 0.75
TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis. Eur J Immunol (2017) 0.75
Immune recognition of irradiated cancer cells. Immunol Rev (2017) 0.75
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature (1985) 5.41
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 4.42
Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol (1985) 4.41
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol (1987) 3.41
BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc Natl Acad Sci U S A (1986) 2.18
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05
Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol (1986) 1.46
Sequence of the porcine transforming growth factor-beta precursor. Nucleic Acids Res (1987) 1.23
Lymphokine-mediated induction of cytolytic activity in a T cell hybridoma. J Immunol (1985) 1.07
Induction of cytotoxic T cell function requires sequential action of three different lymphokines. J Immunol (1983) 1.06
Ontogeny of murine T lymphocytes. I. Maturation of thymocytes induced in vitro by tumor necrosis factor-positive serum (TNF+)1,2. Cell Immunol (1981) 0.94
Lymphokine-induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic response. J Immunol (1985) 0.89
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science (1993) 14.91
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem (1999) 5.81
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 4.42
Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol (1985) 4.41
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med (1992) 4.02
The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A (1991) 3.40
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A (1991) 3.19
Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med (1988) 2.92
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation. J Exp Med (1983) 2.76
Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol (1988) 2.74
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med (1989) 2.68
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol (1986) 2.38
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A (1991) 2.24
Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry (1988) 2.09
Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor. J Exp Med (1984) 2.00
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol (1993) 1.89
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol (1990) 1.83
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol (1987) 1.81
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol (1989) 1.76
Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun (2001) 1.75
A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol (1992) 1.75
Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res (1988) 1.74
Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol (1989) 1.72
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol (2001) 1.58
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol (1991) 1.57
Mediation of cardioprotection by transforming growth factor-beta. Science (1990) 1.52
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49
Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol (1989) 1.46
Functional channel formation associated with cytotoxic T-cell granules. Proc Natl Acad Sci U S A (1986) 1.43
Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res (1988) 1.39
Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action. J Immunol (1989) 1.39
Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med (1990) 1.39
Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart (2005) 1.38
Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res (1987) 1.38
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol (1989) 1.35
Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol (1998) 1.34
Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol (1983) 1.33
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med (1990) 1.28
Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol (1993) 1.27
Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant (2001) 1.26
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med (1989) 1.26
Induction of cytokine production from human monocytes stimulated with alginate. J Immunother (1991) (1991) 1.23
The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction. J Immunol (1988) 1.20
Different forms of Ly-5 within the T-cell lineage. Immunogenetics (1983) 1.20
Role of oxygen in T cell-mediated cytolysis. J Immunol (1982) 1.18
Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J Immunol (1984) 1.17
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol (1991) 1.16
Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation (1992) 1.16
Immunohistochemical localization of Toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Oral Microbiol Immunol (2003) 1.15
Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor. J Exp Med (1989) 1.14
Epididymal epithelium: its contribution to the formation of a luminal fluid microenvironment. Microsc Res Tech (1995) 1.13
Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem (1994) 1.13
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem (2000) 1.12
Alginate polycation microcapsules. II. Some functional properties. Biomaterials (1996) 1.11
Alginate polycation microcapsules. I. Interaction between alginate and polycation. Biomaterials (1996) 1.11
TGF-beta: a possible autocrine immune regulator. Ciba Found Symp (1991) 1.09
Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells. J Immunol (1985) 1.09
Characterization of interleukin 2-dependent cytotoxic T-cell clones: specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera. Cancer Res (1983) 1.07